Xcout IntelCarterra, Inc.
Carterra, Inc. is based in Salt Lake City, Utah, and specializes in high-throughput antibody screening and characterization platforms for life sciences research and drug discovery.
Subscribe to see Carterra, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Carterra, Inc. at a glance
Carterra, Inc. is an analytical instruments company headquartered in United States. It has raised at least $33.6M across the 5 funding rounds on record. Its most recent funding round raised $5M in December 2023. Xcout tracks 5 named people at Carterra, Inc., including Josh Eckman (Chief Executive Officer).
Carterra, Inc. leadership
- Josh EckmanChief Executive Officer
- Joseph D KeeganExecutive Chairman
- Alexander HerzickDirector
- Jack BallDirector
- John LilligDirector
Carterra, Inc. funding rounds
At least $33.6M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $5M | — | |
| SEC Form D filing | $8.1M | — | |
| SEC Form D filing | $6M | — | |
| SEC Form D filing | $4.5M | — | |
| — | $10M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Carterra, Inc. competitors
A few of Carterra, Inc.'s closest competitors — see the full list of competitors and alternatives →
Inimmune Corporation is a privately held biotechnology research company located in Missoula, Montana. The company specializes in the discovery and development of innovative therapeutics and related research solutions.
PhenomeX, formerly Berkeley Lights, developed automated platforms and consumables for single-cell analysis, including cell isolation, screening, and characterization. Its customers included biopharmaceutical companies, academic researchers, and clinical or translational laboratories conducting antibody discovery, cell-line development, and other life-science research.
3T Biosciences is an immunotherapy company headquartered in South San Francisco, California. The company focuses on discovering novel T-cell receptor targets to build innovative treatments for cancer.
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
CDR-Life Inc. is a biotechnology company based in Zürich, Switzerland, developing highly selective T-cell engagers (TCEs) through its proprietary M-gager platform to treat cancer and autoimmune diseases.
Exogene combines generative artificial intelligence with high-throughput TCR screening in the laboratory to design developable TCR-based medicines. Headquartered in Oxford, United Kingdom, the company focuses on eradicating cancer through next-generation therapeutics.
Get Carterra, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Carterra, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Carterra, Inc. in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access